Majzner_Lab (@Majzner

Majzner_Lab

384 posts

Majzner_Lab

@Majzner_Lab

Robbie Majzner's Lab at Dana Farber. Focus on CAR T cell signaling & engineering, cancer immunotherapy & ganglioside biology. Interested in curing kids!

Boston, MA but heart in 🇮🇱

Joined April 2021

Majzner_Lab
@Majzner_Lab
Mar 9, 2023
Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. rdcu.be/c7avS
68K
Majzner_Lab
@Majzner_Lab
Nov 3, 2023
Replying to @BMWE_
Thank you for your moral clarity, your support of Israel and hope for a future of peace. My holocaust survivor grandparents would be very touched by your words.
22K
Majzner_Lab
@Majzner_Lab
Feb 7, 2022
Our experience w/GD2 CAR T cells in 4 patients with DIPG/DMG was published today. This work taught us much about how to safely & effectively treat this disease w/CARs. Deeply grateful to patients & families who bravely trusted us as we learned together.nature.com/articles/s4158… 1/
Majzner_Lab
@Majzner_Lab
Jul 31, 2023
Excited to share that @Majzner_Lab is moving to @DanaFarber @DFBC_PedCare as of Sept. Bittersweet to leave Stanford, but looking forward to growing our research program both in the lab and in the clinic. Hiring postdocs, scientists & lab manager- please reach out if interested!
56K
Majzner_Lab
@Majzner_Lab
Jan 18, 2022
My lab at Stanford is hiring. We work on engineering new cancer immunotherapies and understanding their activity in early phase trials. Open postdoc positions as well as a technician with animal experience. Contact me if interested! Please retweet!
Majzner_Lab
@Majzner_Lab
Dec 29, 2022
Thank you @NatureMedicine for your recognition of the growing lab! Excited for the new therapies we will bring to children with cancer in the next few years.
Nature Medicine
@NatureMedicine
Dec 29, 2022
11 trailblazing early-career researchers, shaping the future of #medicine, share what they are most excited about right now and where their research is going in the next 5 years - read now: go.nature.com/3C8xLYS
37K
Majzner_Lab
@Majzner_Lab
Apr 6, 2023
Really happy to see the wonderful work from colleagues in Rome using 3rd gen GD2 CARs for neuroblastoma. This is the largest series of CAR T responses in a solid tumor to date & the fact that it’s in a pediatric cancer is awesome! Bravo!
nejm.org
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma | NEJM
Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neurobl...
28K
Majzner_Lab
@Majzner_Lab
Jan 13, 2022
Happy to share our lab's first manuscript. In work led by @JTheruvath_MD, we tested a combo of FDA approved anti-GD2 with blockade of CD47, a macrophage checkpoint. Blocking CD47 unleashes patients' macrophages to phagocytose or 'eat' cancer cells. Combo was highly effective! 1/
Saheli Sadanand
@SaheliSadanand
Jan 13, 2022
📢 New in @NatureMedicine! Great work led by @Majzner_Lab @JTheruvath_MD shows that the combo of anti-GD2 + CD47 blockade ⬆️ anti-tumor activity in 🐭 models of #neuroblastoma, #osteosarcoma & #lungcancer by modulating #macrophage activity #immunotherapy nature.com/articles/s4159…
Majzner_Lab
@Majzner_Lab
Jun 16, 2022
Happy to be a part of NexTGen team to solve the challenge of solid tumors in children. Cell therapies can get us there! Led by Martin Pule & Cath Bollard, grant will support 5yr research incl. 3 trials of CAR T in kids!
med.stanford.edu
Nine Stanford scientists receive cancer research funding totaling $13 million
The funding, from Cancer Grand Challenges, will help the researchers address difficult problems in cancer prevention, treatment-resistant cancers and therapies for pediatric solid tumors.
Majzner_Lab
@Majzner_Lab
Apr 3, 2022
Final version of the paper is up…nature.com/articles/s4158… …much more to come at AACR next week…
Majzner_Lab
@Majzner_Lab
Feb 7, 2022
Our experience w/GD2 CAR T cells in 4 patients with DIPG/DMG was published today. This work taught us much about how to safely & effectively treat this disease w/CARs. Deeply grateful to patients & families who bravely trusted us as we learned together.nature.com/articles/s4158… 1/
Majzner_Lab
@Majzner_Lab
Oct 31, 2023
Replying to @ProfKFranke
This is a pathetic take on a horrible massacre. Your academic posturing reeks of moral cowardice - calling murder, torture, and rape "military action/response" - shameful! @Columbia - you are becoming more and more irrelevant to the lives of your alumni.
1.8K
Majzner_Lab
@Majzner_Lab
Apr 11, 2022
⁦@MarcelaMaus⁩ ⁦gave a fantastic talk about the different role of IFNg for CAR T cells for solid vs liquid tumors. Really cool and unexpected biology. Congrats ⁦@SRBailey32⁩ and Rebecca Larson!
Majzner_Lab
@Majzner_Lab
Aug 28, 2023
Looking to hire a lab manager/technician for the new lab at Dana Farber. Please apply to join our group focused on engineering new cell therapies, especially for pediatric cancer. Job description is flexible - experience with mice and T cells preferred. careers.dana-farber.org/job/senior-res…
26K
Majzner_Lab
@Majzner_Lab
Jul 11, 2022
Happy to post about a great collaboration with @KStegmaier_DFCI led by @Nathaniel_Mabe and Min Huang @StanfordPeds where we identify GD2 loss and downregulation as a major resistance mechanism to anti-GD2 antibodies in neuroblastoma nature.com/articles/s4301…